TNF-α通过抑制依赖于巨细胞的胸膜 stromal lymphopoietin 生产来对抗皮肤炎症
Davender Redhu1, Vandana Kumari2, Kristin Franke3
1Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
The Journal of allergy and clinical immunology
|April 6, 2025
概括
瘤坏死因子-α (TNF-α) 通过抑制杆细胞依赖的胸膜 stromal lymphopoietin (TSLP) 生产来抑制湿疹. 这一发现揭示了TNF-α在炎症性皮肤疾病中的保护作用.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 细胞因子信号传递
背景情况:
- 瘤坏死因子-α (TNF-α) 是一种关键的促炎性细胞因子.
- 皮病等炎症性皮肤疾病中和TNF-α可以矛盾地诱导湿疹性病变.
- 在皮肤炎症和湿疹发作中TNF-α的确切作用需要进一步阐明.
研究的目的:
- 研究TNF-α对皮肤炎症的保护作用.
- 确定TNF-α影响皮肤炎症和湿疹的潜在分子机制.
- 在皮肤炎症的背景下,探索TNF-α,巨细胞和TSLP之间的关系.
主要方法:
- 利用皮肤炎症的小鼠模型.
- 采用了各种淘汰赛小鼠模型,包括野生类型,TNF-α缺乏,TSLP受体缺乏,巨细胞缺乏和双缺小鼠.
- 通过物理,临床,组织学,免疫组织化学和生物分析技术评估炎症.
主要成果:
- 缺少TNF-α会加剧皮肤炎症,其特征是巨细胞增生和增加胸膜 stromal lymphopoietin (TSLP) 的产生.
- 巨细胞被确定为TNF-α缺乏小鼠表皮中TSLP产生的主要调解者,损害皮肤屏障功能.
- 在缺乏TNF-α的小鼠中观察到免疫球蛋白的减少,包括IgE.
结论:
- TNF-α在抑制皮肤炎症和预防湿疹方面发挥着至关重要的作用.
- 该机制涉及TNF-α抑制巨细胞依赖TSLP的产生.
- 这些发现突出了TNF-α作为管理炎症性皮肤疾病和预防疹不良反应的潜在治疗点.
相关概念视频
T Cell Types and Functions
689
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
689
Inflammation
52.0K
Overview
52.0K
Inflammatory Response
1.7K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.7K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103


